Cholestanol derivative for combined use

Abstract

The invention provides a cancer chemotherapeutic agent which has fewer side effects and excellent efficacy. The cancer chemotherapeutic agent of the invention includes a cholestanol derivative represented by formula (1): (wherein G represents GlcNAc-Gal-, GlcNAc-Gal-Glc-, Fuc-Gal-, Gal-Glc-, Gal-, or GlcNAc-) or a cyclodextrin inclusion compound thereof, and an anti-cancer agent.

1 . A cancer chemotherapeutic agent comprising, in combination, a cholestanol derivative represented by formula (1): 
       
         
           
           
               
               
           
         
         (wherein G represents GlcNAc-Gal-, or GlcNAc- or a cyclodextrin inclusion compound thereof, and an anti-cancer agent selected from the group consisting of Paclitaxel, Docetaxcel, 5-fluorouracil, Cisplatin, Oxaliplatin, Pemetrexed, Cyclophosphamide, and Irinotecan. 
       
     
     
         2 - 10 . (canceled) 
     
     
         11 . The cancer chemotherapeutic agent of  claim 1 , which is a compounding agent. 
     
     
         12 . The cancer chemotherapeutic agent of  claim 11 , wherein the cholestanol derivative in the compounding agent is a liposomal formulation. 
     
     
         13 . The cancer chemotherapeutic agent of  claim 1 , which is in the form of a kit comprising a drug comprising a cholestanol derivative and a drug comprising an anti-cancer agent. 
     
     
         14 . The cancer chemotherapeutic agent of  claim 13 , wherein the drug comprising a cholestanol derivative is a liposomal formulation. 
     
     
         15 . A method of providing chemotherapy to a cancer patient in need thereof, the method comprising administering to the patient a cholestanol derivative represented by formula (1): 
       
         
           
           
               
               
           
         
         wherein G represents GlcNAc-Gal or GlcNAc- or a cyclodextrin inclusion compound thereof, and an anti-cancer agent selected from the group consisting of Paclitaxel, Docetaxcel, 5-fluorouracil, Cisplatin, Oxaliplatin, Pemetrexed, Cyclophosphamide, and Irinotecan. 
       
     
     
         16 . The method of  claim 15 , wherein the cholestanol derivative and the anti-cancer agent are administered simultaneously. 
     
     
         17 . The method of  claim 15 , wherein the cholestanol derivative and the anti-cancer agent are administered separately. 
     
     
         18 . The method of  claim 15 , wherein the cholestanol derivative and the anti-cancer agent are administered intermittently.